This study tests a drug called lanifibranor in 1000 adults with NASH (a fatty liver disease) and moderate liver scarring (stages F2 or F3). The goal is to see if the drug can reverse the scarring and reduce liver inflammation over 72 weeks. Participants are randomly assigned to r…
Phase: PHASE3 • Sponsor: Inventiva Pharma • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC